Prospera Donor-Derived Cell-Free DNA Transplant Monitoring Market

SNP-based next-generation sequencing (NGS) leads the Prospera donor-derived cell-free DNA transplant monitoring market with a 47.0% share in 2026, followed by transplant centers at 39.8% by end user and acute rejection detection at 38.7% by application. Adoption reflects demand for non-invasive graft monitoring, while testing costs and clinical validation remain key constraints.